|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
106 primary ITP patients (16 with newly-diagnosed ITP, 16 with persistent ITP and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
|
31840311 |
2020 |
|
Immune thrombocytopenic purpura
|
0.020 |
Biomarker
|
disease |
BEFREE |
106 primary ITP patients (16 with newly-diagnosed ITP, 16 with persistent ITP and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
|
31840311 |
2020 |
|
Immune System Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
106 primary ITP patients (16 with newly-diagnosed ITP, 16 with persistent ITP and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
|
31840311 |
2020 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions.
|
31640798 |
2019 |
|
Adult Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions.
|
31640798 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The patient was diagnosed as indolent T-LPD and DLBCL finally.
|
31027102 |
2019 |
|
Intestinal Obstruction
|
0.010 |
Biomarker
|
disease |
BEFREE |
The diagnosis of T-LPD should be made cautiously in case with progressing symptoms such as intestinal obstruction.
|
31027102 |
2019 |
|
Aggressive Non-Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Early detection of high-grade transformation of T-LPD or the coexistence of aggressive lymphoma is essential for the patient.
|
31027102 |
2019 |
|
Glioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The lower fatty acyl pool may be mediated by the lower protein expression levels of long-chain acyl-CoA synthetase 1 (ACSL1), ACSL4, and very long-chain acyl-CoA synthetase 3 (ACSVL3) in IDH1 mutant glioma.
|
30596429 |
2019 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
A 13-year-old boy presented to our clinic with a raised tumor with PCSM-LPD histology and was successfully treated with ultra-low-dose radiation therapy.
|
30548331 |
2019 |
|
Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form
|
0.010 |
Biomarker
|
disease |
BEFREE |
Primary acute or chronic active Epstein-Barr virus infection triggers EBV+ T-LPD's onset and the disease involves clonal proliferation of infected T-cells with activated cytotoxic phenotype.
|
30519236 |
2018 |
|
Systemic Scleroderma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> VICM and BGM levels were increased in early compared with late dSSc (<i>p</i>< =0.023).
|
30457356 |
2019 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders (EBV<sup>+</sup> T/NK LPD) encompass a heterogeneous group of disorders, including chronic active Epstein-Barr virus infection (CAEBV), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), systemic EBV<sup>+</sup> T-cell lymphoma of childhood and hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) and so on, predominantly affecting children and young adults with high mortality.
|
30356785 |
2018 |
|
Hydroa vacciniforme-like lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders (EBV<sup>+</sup> T/NK LPD) encompass a heterogeneous group of disorders, including chronic active Epstein-Barr virus infection (CAEBV), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), systemic EBV<sup>+</sup> T-cell lymphoma of childhood and hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) and so on, predominantly affecting children and young adults with high mortality.
|
30356785 |
2018 |
|
High Grade Lymphoma (neoplasm)
|
0.010 |
Biomarker
|
disease |
BEFREE |
We present an unusual case of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression, Recognition of this unusual immunophenotype of indolent T-cell LPD of GI helps to eschew misdiagnosis of B-cell and other high grade lymphomas and inappropriate aggressive treatment.
|
30342536 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that testing for CD13 expression in routine flow cytometry panels could help to discriminate WM/LPL from other B-LPD.
|
30198568 |
2019 |
|
Malignant lymphoma - lymphoplasmacytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that testing for CD13 expression in routine flow cytometry panels could help to discriminate WM/LPL from other B-LPD.
|
30198568 |
2019 |
|
Long QT Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
The disagreement between BGM and MM <15 ms in all, in controls, and in LQTS was respectively 57%, 63% and 54%.
|
29887480 |
2018 |
|
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Furthermore, KA supplementation reversed the elevation in p66Shc and FoxO3a expression in the muscles of CKD + LPD rats.
|
29855350 |
2018 |
|
Lymphomatoid Papulosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
CD30+ LPD include lymphomatoid papulosis, primary cutaneous anaplastic large-cell lymphoma, and borderline lesions.
|
29719017 |
2018 |
|
Lymphoproliferative Disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Primary intestinal Epstein-Barr virus [EBV]-associated natural killer/T-cell lymphoproliferative disorder [PIEBV+ NK/T-LPD] is a rare clinical entity, which is difficult to differentiate from inflammatory bowel disease [IBD].
|
29635312 |
2018 |
|
Inflammatory Bowel Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Primary intestinal Epstein-Barr virus [EBV]-associated natural killer/T-cell lymphoproliferative disorder [PIEBV+ NK/T-LPD] is a rare clinical entity, which is difficult to differentiate from inflammatory bowel disease [IBD].
|
29635312 |
2018 |
|
Malignant Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The Danish "Suspicious" group was allocated to the BG I, II, III, IV, V and VI with a malignancy risk of 36.4%, 13.3%, 17.2%, 16.1%, 55.3% and 88.2%, respectively.
|
29510805 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The Danish "Suspicious" group was allocated to the BG I, II, III, IV, V and VI with a malignancy risk of 36.4%, 13.3%, 17.2%, 16.1%, 55.3% and 88.2%, respectively.
|
29510805 |
2018 |